Introduction

For nearly two decades, GLP-1 receptor agonists have steadily reshaped metabolic care since the first agent reached the U.S. market in 2005. Initially developed for Type II diabetes, these medications quickly proved their ability to improve glycemic control and significantly lower A1C. Over time, their role expanded beyond glucose management, becoming widely recognized for promoting weight loss through appetite suppression and earlier satiety. Additional benefits, including cardiovascular risk reduction and kidney-protective effects, have further solidified their place in therapy. In 2025, polling from the Kaiser Family Foundation (KFF) reported that 1 in 8 U.S. adults were currently taking a GLP-1 medication for weight loss, diabetes, or another indication, highlighting just how mainstream these therapies have become.

Meanwhile, data from the Centers for Disease Control and Prevention (CDC) show that over 40% of U.S. adults are living with obesity, underscoring the growing severity of the obesity epidemic. The CDC map below illustrates obesity prevalence across the U.S. As obesity rates continue to rise, GLP-1 therapies have emerged as central players in addressing one of the nation’s most urgent public health challenges.

Despite their popularity and clinical benefits, GLP-1 therapies are not without barriers. High cost, gastrointestinal adverse effects, and the burden of weekly subcutaneous injections can limit initiation and long-term adherence. For some patients, needle aversion alone is enough to avoid treatment. That landscape shifted in December 2025, when the U.S. Food and Drug Administration (FDA) approved a once-daily oral tablet version of Wegovy (semaglutide) for chronic weight management, with availability beginning in January 2026. A report by health data firm Truveta found that within the first six weeks of the oral Wegovy launch, 21.1% of patients on the pill had transitioned from an injectable version of Wegovy, while 15.8% had switched from Zepbound. The arrival of an oral option has the potential to expand access. As questions inevitably increase, pharmacists will be on the front lines, making now the perfect opportunity to review what this new formulation means for practice and the evolving obesity treatment landscape. 

Background: GLP-1 Therapy Landscape

GLP-1 receptor agonists work by mimicking the body’s natural GLP-1 hormone, which plays several key roles in regulating metabolism:

• Stimulates glucose-dependent insulin secretion from the pancreas
• Suppresses glucagon release, helping to prevent excessive glucose production
• Slows gastric emptying, promoting a feeling of fullness

Together, these effects lead to lower blood glucose levels and weight loss by reducing appetite and increasing early satiety, making GLP-1 therapies powerful tools for both diabetes and obesity management.

The table below provides an overview of available GLP-1 therapies, including the newly approved oral Wegovy.

Besides diabetes and obesity management, GLP-1 drugs have shown many other potential benefits including:

• Lowering blood pressure
• Improving lipid disorders
• Improving fatty liver disease
• Reducing cardiovascular risk
• Decreases inflammation
• Reducing risk of kidney disease

It is common for patients starting GLP-1 therapy to experience side effects during the first few weeks, including nausea, vomiting, headache, dizziness, and diarrhea. These effects are usually temporary and tend to subside as the body adjusts, which is why GLP-1 medications are typically titrated from a low dose to a higher dose to help minimize discomfort. 

Although rare, serious adverse events can occur, including gallstones, pancreatitis, medullary thyroid cancer, acute kidney injury, and worsening of diabetes-related retinopathy. Monitoring and patient counseling are essential to help identify and manage these risks early.

Is Oral Wegovy the Same as Injectable Wegovy?

So, with all that context, let’s dive into the pill form of Wegovy and answer questions on how this may or may not differ from the standard injection.

Wegovy (semaglutide) tablets are 25 mg once daily oral tablets designed for chronic weight management and cardiovascular risk reduction. They are designed to be used alone and should not be combined with other GLP-1 injections. The oral tablets contain the same active ingredient as the injectable formulation, with an identical mechanism of action and comparable safety and efficacy profiles demonstrated in clinical trials.

Data from the OASIS 4 (oral semaglutide) and STEP 5 (injectable semaglutide) trials highlight similar outcomes across key endpoints. The table below provides a side-by-side comparison of selected results from these studies.

The primary difference between the injection and the pill lies in how the drug is absorbed. The oral Wegovy tablet uses a technology called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) to overcome the low bioavailability typical of oral semaglutide. SNAC works by creating a temporary, localized pH-buffering effect that allows semaglutide to pass directly through the stomach lining into the bloodstream, protecting it from enzymatic degradation along the way. The image below illustrates the absorption mechanism and the protective role of SNAC. 

To achieve maximum benefit, Wegovy tablets should be taken on an empty stomach first thing in the morning, with no more than 4 oz of water, and at least 30 minutes before the first meal of the day. It is important to note that injectable Wegovy can be administered without regard to food, beverages, or time of day.

Another key difference between the two formulations is dosing flexibility. The injectable formulation is manufactured in multiple dose strengths to allow for stepwise titration:

• 0.25 mg once weekly for 4 weeks
• 0.5 mg once weekly for 4 weeks
• 1 mg once weekly for 4 weeks
• 1.7 mg once weekly for 4 weeks
• Maintenance dose: 2.4 mg once weekly

The oral tablet is only available in a single 25 mg strength offering a fixed-dose daily regimen. A higher milligram dose is required to achieve therapeutic systemic exposure. Although the oral tablet does not incorporate a stepwise titration schedule, clinical trial data demonstrated acceptable tolerability with the fixed dose-regimen.

What About Rybelysus?

You might be wondering: What about Rybelsus? After all, it’s also an oral formulation of semaglutide. While it is true that there are now two oral semaglutide products on the market, they differ significantly in indication and dosing.

Oral Wegovy is specifically approved for chronic weight management at a 25 mg daily dose, whereas Rybelsus is FDA approved for Type II diabetes with a maximum dose of 14 mg daily. The higher dose used in oral Wegovy is designed to achieve greater weight reduction, while Rybelsus dosing is optimized primarily for glycemic control. Although Rybelsus can still promote modest weight loss, oral Wegovy is formulated and studied specifically for obesity treatment at a higher therapeutic exposure. 

Despite these differences in indication and dosing, both products contain semaglutide and therefore share a similar mechanism of action and adverse effect profile.

Advantages and Challenges of Oral GLP-1 Therapy

So how does oral Wegovy stack up against the injectable version? The chart below highlights the key advantages and challenges of the oral formulation.

The Bottom Line on the Outlook of Oral GLP-1 Therapy

The introduction of oral Wegovy marks a significant advance in obesity management, offering patients a convenient, needle-free alternative to the weekly injectable while maintaining a comparable safety and efficacy profile. With over 40% of U.S. adults living with obesity, this new formulation provides an important tool to help address one of the nation’s most pressing public health challenges.

The role of pharmacists is pivotal to guide patients on proper administration, emphasizing the importance of taking the tablet on an empty stomach with limited water, managing gastrointestinal side effects, and supporting daily adherence are all key to achieving the best outcomes.

While oral Wegovy removes the injection burden and may improve patient acceptance, challenges such as variable absorption, strict dosing requirements, and cost considerations remain. By understanding these nuances and providing proactive counseling, pharmacists can help patients’ safety and effectively use oral Wegovy, ultimately contributing to broader efforts to combat obesity and improving long-term metabolic health in the U.S.

APPE Student, Hailey Montour

References

Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(5):979-994. doi:10.1007/s11154-022-09735-8

BioSpace. Oral Wegovy brings in thousands of new GLP-1 patients. https://www.biospace.com/business/oral-wegovy-brings-in-thousands-of-new-glp-1-patients. Accessed February 25, 2026.

Centers for Disease Control and Prevention. Adult obesity prevalence maps. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html. Accessed February 25, 2026.

Centers for Disease Control and Prevention. Summary health statistics: National Health Interview Survey, 2021–August 2023. https://www.cdc.gov/nchs/products/databriefs/db508.htm#:~:text=2021%E2%80%93August%202023.-,Summary,adults%20did%20not%20change%20significantly. Accessed February 25, 2026.

Cleveland Clinic. GLP-1 agonists. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists. Accessed February 25, 2026.

Kaiser Family Foundation. 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes, or another condition, even as half say the drugs are difficult to afford. https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/. Accessed February 25, 2026.

Latif W, Lambrinos KJ, Patel P, et al. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs) [Updated 2024 Feb 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572151/. Accessed February 25, 2026.

NovoMedlink. Wegovy: Obesity treatments. https://www.novomedlink.com/obesity/products/treatments/wegovy.html?_gl=1*18bf07x*_ga*MzY1MjUwMzQxLjE3NzIwMzE3NTc.*_ga_F40L5513K4*czE3NzIwMzE3NTYkbzEkZzAkdDE3NzIwMzE3NTYkajYwJGwwJGgw. Accessed February 25, 2026.